Drug Profile
Research programme: monoclonal antibody-based therapeutics - John Hopkins University/Eisai Inc
Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator John Hopkins University; Morphotek
- Developer Eisai Inc; John Hopkins University
- Class 2 ring heterocyclic compounds; Antineoplastics; Cyclic ethers; Furans; Immunoconjugates; Ketones; Macrocyclic compounds; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Cadherin modulators; Receptor protein-tyrosine kinase modulators; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 06 Sep 2017 Morphotek enters into a collaboration with John Hopkins University for development of monoclonal antibody-based therapeutics
- 06 Sep 2017 Early research in Cancer in USA (Parenteral)